The clinical case of successful combined treatment of refractory arterial hypertension. Case report

封面

如何引用文章

全文:

详细

In recent years, there has been an increase of patients with arterial hypertension, one of the variants of which is refractory arterial hypertension. This unfavorable clinical variant of the course of hypertension worries clinicians, due to the higher risk of developing cardiovascular complications, realizing the need for a better control of blood pressure. The presented clinical case demonstrates the successful combined treatment of refractory hypertension using antihypertensive therapy and renal denervation.

作者简介

Tatiana Solntseva

National Medical Research Center of Cardiology

编辑信件的主要联系方式.
Email: tatanasolnceva372@gmail.com
ORCID iD: 0000-0002-7381-7818

клин. ординатор отд. гипертонии Института клинической кардиологии им. А.Л. Мясникова

俄罗斯联邦, Moscow

Anastasiia Denisova

National Medical Research Center of Cardiology

Email: tatanasolnceva372@gmail.com
ORCID iD: 0000-0003-2686-3026

врач-кардиолог отд-ния артериальной гипертонии Института клинической кардиологии им. А.Л. Мясникова

俄罗斯联邦, Moscow

Olga Sivakova

National Medical Research Center of Cardiology

Email: tatanasolnceva372@gmail.com
ORCID iD: 0000-0002-0060-095X

канд. мед. наук, зав. отд-нием артериальной гипертонии Института клинической кардиологии им. А.Л. Мясникова

俄罗斯联邦, Moscow

Nikolai Danilov

National Medical Research Center of Cardiology

Email: tatanasolnceva372@gmail.com
ORCID iD: 0000-0001-9853-9087

д-р мед. наук, вед. науч. сотр. отд. гипертонии Института клинической кардиологии им. А.Л. Мясникова

俄罗斯联邦, Moscow

Dmitrii Pevzner

National Medical Research Center of Cardiology

Email: tatanasolnceva372@gmail.com
ORCID iD: 0000-0002-5290-0065

канд. мед. наук, зав. блоком интенсивной терапии отд. неотложной кардиологии Института клинической кардиологии им. А.Л. Мясникова

俄罗斯联邦, Moscow

Irina Chazova

National Medical Research Center of Cardiology

Email: tatanasolnceva372@gmail.com
ORCID iD: 0000-0002-9822-4357

акад. РАН, д-р мед. наук, проф., зам. ген. дир. по научно-экспертной работе ФГБУ «НМИЦ кардиологии», рук. отд. гипертонии Института клинической кардиологии им. А.Л. Мясникова ФГБУ «НМИЦ кардиологии»

俄罗斯联邦, Moscow

参考

  1. Forouzanfar MH, Liu P, Roth GA, et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990–2015. JAMA. 2017;317(2):165-82. doi: 10.1001/jama.2016.19043
  2. Mills KT, Bundy JD, Kelly TN, et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016;134(6):441-50. doi: 10.1161/CIRCULATIONAHA.115.018912
  3. Chia R, Pandey A, Vongpatanasin W. Resistant hypertension-defining the scope of the problem. Prog Cardiovasc Dis. 2020;63(1):46-50. doi: 10.1016/j.pcad.2019.12.006
  4. Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019;16(1):6-31 [Chazova IE, Zhernakova YuV on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6-31 (in Russian)]. doi: 10.26442/2075082X.2019.1.190179
  5. Feidakis A, Panagiotou MR, Tsoukakis E, et al. Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Acute Kidney Injury in Emergency Medical Admissions. J Clin Med. 2021;10(3):412. doi: 10.3390/jcm10030412
  6. Moore PK, Hsu RK, Liu KD. Management of Acute Kidney Injury: Core Curriculum 2018. Am J Kidney Dis. 2018;72(1):136-48. doi: 10.1053/j.ajkd.2017.11.021
  7. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-88. doi: 10.1093/eurheartj/ehz455
  8. Матчин Ю.Г., Григин В.А., Данилов Н.М., и др. Радиочастотная денервация почечных артерий в лечении рефрактерной артериальной гипертонии – результаты годичного наблюдения. Атмосфера. Новости кардиологии. 2013;3:12-8 [Matchin JuG, Grigin VA, Danilov NM, et al. Radiofrequency denervation of the renal arteries in the treatment of refractory arterial hypertension – the results of a one-year follow-up. Atmosphere. Cardiology News. 2013;3:12-8 (in Russian)].
  9. Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017; 390:2160-70. doi: 10.1016/S0140-6736(17)32281-X
  10. Kandzari DE, Kario K, Mahfoud F, et al. The SPYRAL HTN global clinical trial program: rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON MED) of antihypertensive medications. Am Heart J. 2015;171:82-91. doi: 10.1016/j.ahj.2015.08.021
  11. Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;6736:1-11. doi: 10.1016/S0140-6736(18)31082-1
  12. Al Raisi SI, Pouliopoulos J, Swinnen J, et al. Renal Artery Denervation in Resistant Hypertension: The Good, The Bad and The Future. Heart Lung Circ. 2020;29(1):94-101. doi: 10.1016/j.hlc.2019.06.723
  13. Lauder L, Wolf MA, Scholz SS, et al. Renal Denervation: Is It Ready for Prime Time? Curr Cardiol Rep. 2019;21(8):80. doi: 10.1007/s11886-019-1164-2

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Electrocardiogram on admission.

下载 (323KB)
索引源数据
3. Fig. 2. Three-hour blood pressure monitoring on admission.

下载 (69KB)
索引源数据
4. Fig. 3. Three-hour blood pressure monitoring after treatment.

下载 (72KB)
索引源数据

版权所有 © Consilium Medicum, 2021

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 
 


##common.cookie##